@article{705c723a5660446483f860db75f124b2,
title = "Elements of the New Conversation",
abstract = "These comments include established behavioral treatment preceding and augmenting stimulant use to prevent or reduce dosing, nutritional approaches with placebo-controlled evidence, and possible effects of stimulant on micronutrient levels.",
author = "Arnold, {L. Eugene} and Jeanette Johnstone and Barbara Gracious and Hughes, {Andrew J.} and Irene Hatsu and Brenda Leung and Sibley, {Margaret H.}",
note = "Funding Information: Disclosure: Dr. Arnold has received research funding from Noven, Otsuka, Roche / Genentech , Supernus, and YoungLiving, has consulted with Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD), Pfizer , Shire (a Takeda company), Tris Pharma, and Waypoint, and has been on advisory boards for Ironshore, Otsuka, Pfizer, Roche, and Shire. Dr. Sibley has consulted with Takeda and has received royalties from Guilford Press for a book on behavioral treatment for ADHD and Vimeo, Inc. for behavioral treatment training videos. Drs. Johnstone, Gracious, Hughes, Hatsu, and Leung have reported no biomedical financial interests or potential conflicts of interest. ",
year = "2020",
month = dec,
doi = "10.1016/j.jaac.2020.08.438",
language = "English (US)",
volume = "59",
pages = "1310--1311",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier Limited",
number = "12",
}